Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 102.77
(5.02%)
CNY 102.77
(5.02%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 385.41 Million CNY | 27.49% |
| 2022 | 302.3 Million CNY | 58.81% |
| 2021 | 190.36 Million CNY | 588.19% |
| 2020 | 27.66 Million CNY | 0.0% |
| 2019 | - CNY | -100.0% |
| 2018 | 1.31 Million CNY | 0.0% |
| 2017 | - CNY | -100.0% |
| 2016 | 200.33 Thousand CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 108 Million CNY | 3.83% |
| 2024 Q2 | 132.12 Million CNY | 22.33% |
| 2024 Q3 | 143.42 Million CNY | 8.55% |
| 2023 Q4 | 104.02 Million CNY | 67.31% |
| 2023 FY | 385.41 Million CNY | 27.49% |
| 2023 Q3 | 62.17 Million CNY | -44.39% |
| 2023 Q2 | 111.81 Million CNY | 3.43% |
| 2023 Q1 | 108.11 Million CNY | 3.54% |
| 2022 FY | 302.3 Million CNY | 58.81% |
| 2022 Q3 | 92.49 Million CNY | 49.97% |
| 2022 Q2 | 61.67 Million CNY | 41.05% |
| 2022 Q1 | 43.72 Million CNY | -52.36% |
| 2022 Q4 | 104.41 Million CNY | 12.89% |
| 2021 Q2 | 42.4 Million CNY | 0.0% |
| 2021 Q1 | - CNY | 100.0% |
| 2021 FY | 190.36 Million CNY | 588.19% |
| 2021 Q4 | 91.78 Million CNY | 63.4% |
| 2021 Q3 | 56.16 Million CNY | 32.44% |
| 2020 Q4 | -317.42 Thousand CNY | -101.13% |
| 2020 Q3 | 27.97 Million CNY | 0.0% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 FY | 27.66 Million CNY | 0.0% |
| 2020 Q2 | - CNY | 0.0% |
| 2019 FY | - CNY | -100.0% |
| 2019 Q4 | - CNY | 0.0% |
| 2019 Q3 | - CNY | 0.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 FY | 1.31 Million CNY | 0.0% |
| 2017 FY | - CNY | -100.0% |
| 2016 FY | 200.33 Thousand CNY | 0.0% |